虚血性脳卒中後に検出される心房細動の病態生理とリスク (PARADISE)
虚血性脳卒中後に検出される心房細動の病態生理学とリスク (PARADISE): 前向き非介入コホート研究
This prospective non-interventional cohort study investigates the pathophysiology of Atrial Fibrillation Detected After Stroke or transient ischemic attack (AFDAS) by comparing the autonomic function and inflammation between patients with AFDAS, patients with atrial fibrillation (AF) diagnosed before the ischemic event or known AF (KAF), and patients with normal sinus rhythm (NSR) after 14 day of cardiac monitoring following the event onset.
調査の概要
詳細な説明
This study enrolls patients with acute ischemic stroke at the London Health Sciences Center in London, Ontario, Canada. The heart rhythm of the patients is monitored with a CardioSTAT® Holter device (Icentia) for 14 days after the ischemic event onset. Based on this cardiac monitoring and previous medical history, patients are stratified into three groups: (a) atrial fibrillation detected after stroke or transient ischemic attack (AFDAS), (b) atrial fibrillation diagnosed before the ischemic event or known AF (KAF), and (c) normal sinus rhythm (NSR).
Autonomic function is assessed by the levels of plasma catecholamines, a battery of validated autonomic tests [autonomic reflex screening (ARS)], heart rate variability (HRV) through data obtained by Holter monitoring by standard quantitative analysis methods according to the guidelines of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology and by the analysis of diurnal variation of heart rate. Blood samples are collected for the analysis of inflammatory markers (e.g. CRP, TNF-α, IL-1β, and IL-6), and potential AFDAS predictors such as brain natriuretic peptide (BNP- AFDAS biomarker), endothelin-1 (endothelial dysfunction marker), Lipoprotein(a) [Lp(a)] and thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels, TAFI activity, TAFI single nucleotide polymorphisms (SNPs), apo(a) isoform size and plasma catecholamines levels. Furthermore, specific neuroimaging findings (e.g., specific regions of the insula or its connections) and clinical features (e.g., impaired interoceptive processing, cognitive impairment, etc) are also analyzed. Interoception is assessed using a heartbeat detection task without feedback condition and gait, balance, frailty, and cognitive status in patients are evaluated by the administration of a battery of tests. Stroke recurrence will be assessed by a structured phone interview at 6 and 12 months after the initial stroke.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Ontario
-
London、Ontario、カナダ、N6A 5A5
- University Hospital, London Helath Sciences Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Ischemic stroke and transient ischemic attack patients presenting at the University Hospital of the London Health Science Center, London, Ontario, Canada.
説明
Inclusion Criteria:
- MCA territory-transient ischemic attack or -acute ischemic stroke patients seen in the Emergency Department or admitted to University Hospital, London, Ontario, Canada
- Age ≥ 18 years old
- Patient or Substitute Decision Maker must give written informed consent
Exclusion Criteria:
- Patients with autonomic dysfunction such as Parkinson's disease that can be interfering with outcome assessment based on qualified investigator's judgment.
- Patients taking tricyclic antidepressant (TCAs)
- Patients in whom the acute stroke is primarily hemorrhagic
- Patients with both TIA and atrial fibrillation
- Patients with both TIA and large vessel disease
- Patients with inflammatory diseases
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
AFDAS
patients without history of atrial fibrillation before the qualifying stroke or transient ischemic attack who are diagnosed with atrial fibrillation during the 14 days of monitoring |
|
KAF
atrial fibrillation known before the stroke or transient ischemic attack |
|
NSR
patients without a history of atrial fibrillation who do not develop atrial fibrillation during the 14 days of cardiac monitoring |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Changes and Differences in Autonomic Function
時間枠:Within 48 hours of stroke onset and at 12, 30 and 90 days.
|
Differences in Composite Autonomic Severity Score (CASS) on an 11-point scale between patients with (a) AFDAS, (b) KAF , and (c) NSR |
Within 48 hours of stroke onset and at 12, 30 and 90 days.
|
|
Changes and Differences in Inflammatory Responses
時間枠:Within 48 hours of stroke onset and at 12, 30 and 90 days.
|
Differences in levels of plasma markers or temporal responses (CRP,TNFα, IL-6, IL-1β, etc) between patients with (a) AFDAS, (b)KAF and (c) NSR. |
Within 48 hours of stroke onset and at 12, 30 and 90 days.
|
|
Changes and Differences in Heart Rate Variability (HRV)
時間枠:At 14 days.
|
Differences in HRV parameters between patients with (a) AFDAS, and (b) NSR |
At 14 days.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Biomarkers
時間枠:Within 48 hours of stroke onset, at 12, 30 and 90 days and at 6 months.
|
Differences in levels of plasma markers (BNP,endothelin-1, Lp(a), and TAFI) or neuroimaging/clinical predictors between patients with (a) AFDAS , (b) KAF and (c) NSR |
Within 48 hours of stroke onset, at 12, 30 and 90 days and at 6 months.
|
|
Atrial Fibrillation Burden
時間枠:At 14 days
|
Difference in atrial fibrillation burden (sum of atrial fibrillation episodes for a period of time) of AFDAS subjects with mild stroke/TIA compared to AFDAS subjects with moderate/severe stroke. |
At 14 days
|
|
Gait Impairments
時間枠:At 6 months
|
Differences in gait parameters in patients with a) AFDAS , (b) KAF and (c) NSR. |
At 6 months
|
|
Frailty
時間枠:At 6 months
|
Differences in frailty in patients with (a) AFDAS , (b) KAF and (c) NSR |
At 6 months
|
|
Cognitive Impairment
時間枠:At 6 months
|
Differences in cognition in patients with (a) AFDAS , (b) KAF and (c) NSR |
At 6 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Stroke Recurrence
時間枠:At 90, 180, and 360 days
|
Number of stroke recurrences in patients with (a) AFDAS , (b) KAF and (c) NSR |
At 90, 180, and 360 days
|
|
Death
時間枠:At 90, 180, and 360 days
|
Number of deaths in (a) AFDAS , (b) KAF and (c) NSR groups |
At 90, 180, and 360 days
|
協力者と研究者
協力者
捜査官
- 主任研究者:Luciano A Sposato, MD、Lawson Health Research Institute, London Health Sciences Center, Western University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- R-17-032
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。